Tnfrsf10b-flox Mouse
Common Name
Tnfrsf10b-flox
제품 ID
S-CKO-06384
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-21933-Tnfrsf10b-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Tnfrsf10b-flox Mouse (카탈로그 번호 S-CKO-06384)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Tnfrsf10b-flox
품종 계통계통 ID
CKOCMP-21933-Tnfrsf10b-B6J-VA
유전자명
제품 ID
S-CKO-06384
유전자 별칭
MK, DR5, Ly98, KILLER, TRICKB, TRAILR2, TRICK2A, TRICK2B
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 14
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000022663
NCBI 전사체 ID
NM_020275
타겟 영역
Exon 2
유효 영역 크기
~1.3 kb
유전자 연구 개요
Tnfrsf10b, also known as TRAIL-R2 or DR5, codes for a pro-apoptotic receptor activated by TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) and is involved in apoptosis-related pathways, playing a crucial role in immune surveillance against virus-infected or transformed cells [1,7].
In chronic lymphocytic leukemia (CLL), del(8p) is associated with poor prognosis and fludarabine resistance, and TNFRSF10B is haploinsufficient in 91% of del(8p) CLL cases, involved in modulating fludarabine-induced cell death [1].
In non-small cell lung cancer, certain TNFRSF10B polymorphisms and haplotypes are associated with an increased risk of death [2].
In diabetic kidney disease, TNFRSF10B expression is increased in podocytes, and TRAIL/DR5 signaling via TNFRSF10B promotes podocyte PANoptosis, with podocyte-specific deletion of TNFRSF10B alleviating podocyte and glomerular injury in diabetic mice [3].
In non-small cell lung cancer cells, YIPF2 promotes chemotherapeutic agent-mediated apoptosis by enhancing TNFRSF10B recycling to the plasma membrane [4].
In lung adenocarcinoma, TNFRSF10B mRNA is preferentially expressed in EGFR wild-type tumors, and strong TRAIL-R2 (encoded by TNFRSF10B) expression predicts a poor prognosis [5].
In HPV-positive head and neck squamous cell carcinomas, combining a death agonist antibody against TNFRSF10B with birinapant enhances anti-tumor activity [6].
Hepatitis B virus-triggered autophagy targets TNFRSF10B for degradation, limiting the TNFSF10/TRAIL response, allowing virus-infected cell survival [7].
In conclusion, Tnfrsf10b is essential for apoptosis-related biological processes. Studies using gene-knockout or cell-specific knockout models in various diseases such as leukemia, lung cancer, and diabetic kidney disease have revealed its role in disease prognosis, response to treatment, and disease-related cellular processes. Understanding Tnfrsf10b's functions through these models provides insights into disease mechanisms and potential therapeutic targets.
References：
1. Jondreville, Ludovic, Dehgane, Lea, Doualle, Cecile, Susin, Santos A, Nguyen-Khac, Florence. 2023. del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. In Leukemia, 37, 2221-2230. doi:10.1038/s41375-023-02035-3. https://pubmed.ncbi.nlm.nih.gov/37752286/
2. Schabath, Matthew B, Giuliano, Anna R, Thompson, Zachary J, Beg, Amer A, Haura, Eric B. 2013. TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. In Carcinogenesis, 34, 2525-30. doi:10.1093/carcin/bgt244. https://pubmed.ncbi.nlm.nih.gov/23839018/
3. Lv, Zhimei, Hu, Jinxiu, Su, Hong, Shen, Ning, Wang, Rong. 2024. TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease. In Kidney international, 107, 317-331. doi:10.1016/j.kint.2024.10.026. https://pubmed.ncbi.nlm.nih.gov/39571905/
4. Wang, Yingying, Guo, Sen, Li, Dongmei, Su, Ling, Liu, Xiangguo. 2020. YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. In Cell death & disease, 11, 242. doi:10.1038/s41419-020-2436-x. https://pubmed.ncbi.nlm.nih.gov/32303681/
5. Chang, Wei-Chin, Yeh, Yi-Chen, Ho, Hsiang-Ling, Chou, Teh-Ying. 2022. Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome. In Human pathology, 126, 9-18. doi:10.1016/j.humpath.2022.05.004. https://pubmed.ncbi.nlm.nih.gov/35550831/
6. An, Yi, Jeon, Jun, Sun, Lillian, Van Waes, Carter, Chen, Zhong. 2021. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. In Scientific reports, 11, 6392. doi:10.1038/s41598-021-85589-5. https://pubmed.ncbi.nlm.nih.gov/33737574/
7. Shin, Gu-Choul, Kang, Hong Seok, Lee, Ah Ram, Kim, Kyun-Hwan. 2016. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. In Autophagy, 12, 2451-2466. doi:. https://pubmed.ncbi.nlm.nih.gov/27740879/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.